Unlocking the Potential of RPL26L1: A novel Drug Target and Biomarker for Cancer Treatment

Target Name: RPL26L1

NCBI ID: G51121

RPL26L1

Unlocking the Potential of RPL26L1: A novel Drug Target and Biomarker for Cancer Treatment

Introduction

Ribosomal protein (RPN) L26 is a key regulator of protein synthesis in eukaryotic cells, and its levels have been implicated in various diseases, including cancer. The 26S ribosomal protein L26-like 1 (RPL26L1) is a highly conserved protein that shares 95% identity with RPL26 but has distinct differences in its sequence and function. RPL26L1 has been identified as a potential drug target and biomarker for cancer treatment, and this article will explore its unique features and the potential implications for cancer research.

Structure and Function

RPL26L1 is a 26kDa protein that contains 155 amino acid residues. It has a distinct N-terminal region that includes a putative N-acyl transferase (NAT) domain, a conserved carboxy-terminal region, and a unique C-terminal region that includes a farnesylated cysteine 鈥嬧?媟esidue and a conserved His222 residue. RPL26L1 also has a distinct 5'-end region that includes a unique G-rich substructure and a 5'-end loop.

Functional studies have shown that RPL26L1 plays a critical role in regulating protein synthesis in various cell types. It has been shown to regulate the levels of various proteins, including the cell adhesion molecule E-cadherin and the tumor suppressor protein p53. RPL26L1 has also been shown to promote the translation of specific genes into the cytoplasm, which may contribute to its role in cell migration and invasion.

Drug Target Potential

The potential drug target for RPL26L1 is its unique function as a regulator of protein synthesis and its potential role in cancer. Several studies have shown that inhibiting RPL26L1 function can lead to the inhibition of cell proliferation and the downregulation of various signaling pathways, including the PI3K /Akt signaling pathway. This suggests that RPL26L1 may be a useful drug target for cancer treatment.

Biomarker Potential

The potential use of RPL26L1 as a biomarker for cancer treatment is its ability to be expressed and processed in various cell types, including cancer cells. Several studies have shown that RPL26L1 can be used as a protein biomarker for cancer, including the detection of cancer cells. populations in a variety of samples, such as blood, urine, and tissue samples. Additionally, RPL26L1 has been shown to be expressed in various types of cancer, including breast, lung, and colorectal cancer.

Conclusion

RPL26L1 is a unique protein that has been identified as a potential drug target and biomarker for cancer treatment. Its function as a regulator of protein synthesis and its potential role in cancer biology make it an attractive target for drug development. Further research is needed to fully understand the potential implications of RPL26L1 as a drug target and biomarker for cancer treatment.

Protein Name: Ribosomal Protein L26 Like 1

The "RPL26L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL26L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets